author-photo

P. Armand

Harvard University

53

Papers

388

Citations

Citation Trend

Filter By

Papers (40) Sort By

Journal Conference Others

Sequential Detection of a Temporary Change in Multivariate Time Series

2021 arXiv: Applications
Show All
- Source
- Cite
- Save
Citations (0)
Source term estimate assorted with uncertainties using backward atmospheric transport modelling, Bayesian reconstruction and an ensemble of weather predictions

2020
- P. Armand
Show All
- Source
- Cite
- Save
Citations (0)
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

2020 Oncologist
Show All
- Source
- Cite
- Save
Citations (8)
Itpas v1 - A new Lagrangian Particle Dispersion Model using COSMO weather forecast for parametrizing in-time turbulence

2020
- P. Armand
Show All
- Source
- Cite
- Save
Citations (0)
NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (5)
INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (5)
PCN130 REAL-WORLD DEMOGRAPHICS AND CLINICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL)

2019 Value in Health
Show All
- Source
- Cite
- Save
Citations (0)
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) PATIENTS INITIATED ON ANTI-CANCER THERAPIES IN THE UNITED STATES (US): PB1809

2019
Show All
- Source
- Cite
- Save
Citations (0)
NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR EXTENDED FOLLOW-UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY: S821

2019
Show All
- Source
- Cite
- Save
Citations (1)
PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)